Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet
Am J Transplant
.
2023 Oct;23(10):1483-1484.
doi: 10.1016/j.ajt.2023.05.033.
Epub 2023 Jun 9.
Authors
Flavio Vincenti
1
,
Klemens Budde
2
,
Josep Grinyo
3
,
Lionel Rostaing
4
,
Allan D Kirk
5
,
Christian P Larsen
6
Affiliations
1
Division of Transplant Surgery, University of California, San Francisco, California, USA. Electronic address: Flavio.Vincenti@ucsf.edu.
2
Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
3
Division of Nephrology, University of Barcelona, Barcelona, Spain.
4
Department of Nephrology, Université Grenoble Alples, Saint-Martin- d'hères, France.
5
Department of Surgery, Duke University, Durham, North Carolina, USA.
6
Emory Transplant Center, Emory University, Atlanta, Georgia, USA.
PMID:
37394381
DOI:
10.1016/j.ajt.2023.05.033
No abstract available
Keywords:
Transplant; belatacept; costimulation.
Publication types
Editorial
MeSH terms
Abatacept / therapeutic use
Immunosuppressive Agents* / therapeutic use
Kidney Transplantation*
Substances
Abatacept
Immunosuppressive Agents